Business context and reporting period
The supplied filing is Organovo Holdings, Inc.’s Form 10-Q for the quarter and six months ended September 30, 2021 (fiscal Q2 and first half of fiscal 2022), filed November 8, 2021. This differs from the request metadata naming Vivosim Labs, Inc. The filing describes Organovo as an early-stage biotechnology company developing 3D human tissue and disease models, initially focused on ulcerative colitis and Crohn’s disease, with an intended path toward drug discovery and development.
Financial results and liquidity
Amounts below are in millions of dollars unless stated otherwise. The company reported no revenue in the presented statements; gross margin is therefore not applicable.
| Metric | Three months ended Sep. 30, 2021 | Six months ended Sep. 30, 2021 | Comparable 2020 period |
|---|---|---|---|
| Research and development expense | $0.679 | $1.259 | $0.028 for each period |
| Selling, general and administrative expense | $2.828 | $4.807 | $8.922 and $11.708 |
| Total operating expense / operating loss | $3.507 | $6.066 | $8.950 and $11.736 |
| Net loss | $3.505 | $6.037 | $8.950 and $11.719 |
| Net loss per share, basic and diluted | $0.40 | $0.69 | $1.36 and $1.79 |
| Net cash used in operating activities | Not stated separately | $3.556 | $9.718 |
At September 30, cash and cash equivalents were $33.791 million, restricted cash was $0.111 million, and working capital was $32.6 million. Current liabilities were $1.675 million; the balance sheet reported no debt. Cash and cash equivalents had declined from $37.364 million at March 31. Management said available cash should fund operations for at least 12 months, but anticipated needing additional capital to execute its plan. Fiscal 2022 operating expense guidance was $12–$14 million.
Changes versus the prior comparable period
- First-half net loss improved by $5.682 million and operating cash use decreased by $6.162 million year over year. Management attributed the lower spending largely to the different operating structure following the prior-year change in control and strategic alternatives process.
- R&D expense rose substantially as the company resumed and rebuilt research activity; management said it expected further increases in headcount, R&D activity, and related costs.
- SG&A decreased, principally because of lower personnel and stock-based compensation costs. Current-period corporate costs increased, including patent-related legal expenses.
- Weighted-average shares for the six-month period increased to 8.701 million from 6.547 million. The company raised approximately $0.3 million net through ATM sales in the first half.
Outlook, risks, contingencies, and unusual items
- The business strategy is early-stage and unproven; the company had not identified or developed drug candidates under the new model and expects operating losses as R&D expands. Meaningful revenue and profitability are uncertain.
- Organovo cited risks involving execution of its drug-discovery strategy, access to qualified human cells and skilled staff, dependence on collaborators and service providers, financing availability and potential dilution, and COVID-19-related disruption.
- Cellink and affiliates filed multiple patent inter partes review petitions and a declaratory judgment action; Organovo also filed a patent infringement complaint seeking an injunction and damages. The company assessed the IPR loss likelihood as remote, but deemed an unfavorable outcome in the declaratory judgment action reasonably possible and could not estimate a loss range. No litigation accrual was recorded. Estimated costs were $850,000–$950,000 for each of two groups of IPR proceedings.
- A permanent San Diego lease was expected to commence in fiscal Q3 2022, with approximately 62 months’ term and monthly rent of about $32,000, subject to 3% annual increases. The filing said the lease would result in recognition of a right-of-use asset and liability when commenced.
- Management concluded disclosure controls and procedures were effective at quarter-end and reported no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Confirm the filing identity and period: the supplied document is Organovo Holdings’ 10-Q for the period ended September 30, 2021, not a Vivosim Labs filing.
- Track cash burn against the $12–$14 million fiscal 2022 operating expense outlook and management’s stated 12-month liquidity expectation.
- Assess progress in developing disease models and drug candidates, since the strategy was unproven and the company reported no revenue.
- Monitor the Cellink patent proceedings, associated legal spending, and any change to the company’s loss-contingency assessments.
- Review future capital raises, ATM usage, and potential dilution; the company disclosed substantial remaining shelf and ATM capacity.